At Apheris, we are building the future of how AI is applied in pharmaceutical R&D.

We enable leading pharmaceutical teams to discover and develop drugs faster by hosting the industry’s largest federated data networks for drug discovery AI, spanning co-folding, ADMET, and antibody developability.

Across these networks, models are trained on proprietary industry datasets to achieve higher performance and broader applicability while keeping data control and IP protected. We deliver these superior models through drug discovery applications that enable teams to run them at scale, further customize them, and integrate them into existing R&D workflows.

• AI Structural Biology (AISB) Network: Eight top-20 pharma companies collaborate in the field of co-folding, structure-based binding affinity predictions and antibody design.
• ADMET Network: Five top-50 pharma and biotechs collaborate to improve small-molecule property prediction and expand to fur...